Plain-English translation of NCT06322407 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a treatment called stellate ganglion block (SGB)—a minimally invasive procedure where a doctor injects medication near a nerve bundle in your neck to reduce migraine pain. Half of participants will receive this procedure plus standard migraine medications (topiramate and ibuprofen), while the other half will receive medication alone. The goal is to see whether adding this procedure helps people with chronic migraines who haven't benefited from traditional drug treatments.
Many people with chronic migraines don't respond well enough to standard medications, leaving them with few other options. This trial is exploring whether this nerve-blocking procedure could offer a safe, minimally invasive alternative or addition to medications for people whose migraines have resisted standard treatments.
You likely qualify if…
You likely don't qualify if…
If you join the procedure group, you'll receive four nerve block injections over four weeks (one per week), given in your neck under ultrasound guidance—each takes about 20–30 minutes. You'll also take the standard migraine medications daily throughout the study. If you're in the medication-only group, you'll simply take the two standard medications as prescribed. The study will follow you for several weeks to track how your migraines improve and how well you tolerate the treatment.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
China
Sponsor
Beijing Tiantan Hospital
Enrollment target
~206 participants
Started
June 2024
Primary completion
December 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 65 Years
Last updated on clinicaltrials.gov in January 2025.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.